These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26202550)

  • 21. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
    Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
    Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
    Hsu KH; Ho CC; Hsia TC; Tseng JS; Su KY; Wu MF; Chiu KL; Yang TY; Chen KC; Ooi H; Wu TC; Chen HJ; Chen HY; Chang CS; Hsu CP; Hsia JY; Chuang CY; Lin CH; Chen JJ; Chen KY; Liao WY; Shih JY; Yu SL; Yu CJ; Yang PC; Chang GC
    PLoS One; 2015; 10(3):e0120852. PubMed ID: 25789627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
    Paik PK; Arcila ME; Fara M; Sima CS; Miller VA; Kris MG; Ladanyi M; Riely GJ
    J Clin Oncol; 2011 May; 29(15):2046-51. PubMed ID: 21483012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old.
    Forest F; Patoir A; Dal-Col P; Da Cruz V; Camy F; Stachowicz ML; Bayle-Bleuez S; Fournel P; Karpathiou G; Péoc'h M
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):667-671. PubMed ID: 30095461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients.
    Gorukmez O; Yakut T; Gorukmez O; Sag SO; Karkucak M; Kanat O
    Asian Pac J Cancer Prev; 2016; 17(3):1175-9. PubMed ID: 27039744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
    Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
    World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
    Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
    PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
    Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
    Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?
    Ma SS; Wang RR; Peng Q; Liu Y; Qian JY; Li MJ; Li K; Huang ZY; Wu LL; Xie D
    Thorac Cancer; 2024 Mar; 15(9):715-721. PubMed ID: 38362771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.